Initial diagnosis and management of chronic obstructive pulmonary disease in Australia: views from the coal face by Bereznicki, BJ et al.
A
cc
ep
te
d 
A
rti
cl
e
 
Initial diagnosis and management of chronic obstructive pulmonary disease in 
Australia: views from the coal face 
 
Author details:  
Bonnie Bereznicki, Lecturer – University of Tasmania, Hobart, Tasmania 
(author contribution: 60%) 
Haydn Walters, Professorial Fellow – University of Tasmania, Hobart, Tasmania 
(author contribution: 10%);  
Julia Walters, Senior Research Fellow – University of Tasmania, Hobart, Tasmania 
(author contribution: 10%);  
Gregory Peterson, Associate Dean (Research) – University of Tasmania, Hobart, 
Tasmania (author contribution: 10%);  
Luke Bereznicki, Deputy Head (Medicine) – University of Tasmania, Hobart, Tasmania 
(author contribution: 10%) 
 
Authors’ affiliation: School of Medicine, University of Tasmania 
 
Corresponding author: 
Bonnie Bereznicki 
School of Medicine (Pharmacy), University of Tasmania 
Private Bag 26 Hobart TAS 7001 
Email: Bonnie.Bereznicki@utas.edu.au 
Telephone: 03 6226 4624 
 
Acknowledgements: 
This study was funded by the University of Tasmania’s Faculty of Health’s strategic 
seed funding scheme.  
 
Abstract: 
Background: Early diagnosis and management can mitigate the long-term morbidity and 
mortality of chronic obstructive pulmonary disease (COPD).  
Aim: To gain insights into the initial diagnostic process and early management of COPD
 
by Australian general practitioners (GPs).  
Methods: A random sample of Australian GPs was invited to complete a postal survey, 
which assessed familiarity with and use of contemporary practice guidelines, diagnostic 
criteria, and management preferences for COPD. 
Results: Two hundred and thirty-three GPs completed the survey. While most GPs 
based a COPD diagnosis on smoking history (94.4%), symptoms (91.0%) and 
spirometry (88.8%), only 39.9% of respondents recorded a formal diagnosis of COPD 
after the patient’s first symptomatic presentation. Tiotropium was the preferred 
treatment in 77.3% of GPs for the initial management of COPD, while only 27.5% 
routinely recommended pulmonary rehabilitation. GPs routinely recorded patients’ 
smoking status and offered smoking cessation advice, but the timing of this advice 
varied. Less than half of the respondents routinely used COPD management guidelines, 
or tools and resources provided by the Australian Lung Foundation. 
Conclusion: There is scope for major improvement in GPs’ familiarity with and use of 
COPD management guidelines, and readily available tools and resources. Some 
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systematic issues were highlighted in the Australian primary care setting, such as a 
reactive and relatively passive and delayed approach to diagnosis, potentially delayed 
smoking cessation advice and under-utilisation of pulmonary rehabilitation. There is an 
urgent need to devise strategies for improving patient outcomes in COPD using 
resources that are readily available. 
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Introduction 
Chronic obstructive pulmonary disease (COPD), which is largely a preventable 
smoking-related condition, is a major cause of disability, hospital admission and 
premature death in Australia. Approximately 2 million Australians are estimated to have 
COPD,1 and the prevalence is likely to escalate as the population ages.  
Early diagnosis and appropriate management will slow the progression of COPD.2 For a 
disease where decline is largely preventable, the sight of patients dying slowly of COPD 
should be a rarity – sadly it is becoming more common.2 COPD is the fourth leading 
cause of death worldwide and by 2020 it is estimated that it will be the third leading 
cause of death.3 Depending on disease severity, between 40-70% of patients with COPD 
will die within five years of being diagnosed, indicating how late substantive diagnosis 
is established.4 
Under-diagnosis and under-treatment of COPD contribute significantly to the burden of 
human misery and healthcare costs. Despite widely distributed evidence-based 
management guidelines,5,6 knowledge of and adherence to these guidelines amongst 
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doctors remains suboptimal.7-12 In Australia, more than 40% of patients with COPD do 
not have a formal diagnosis from their doctors, and less than 50% have ever been 
prescribed medication for their breathing and are taking the important steps critical to 
slow disease progression.11 Primary healthcare professionals need to know about the 
importance of early detection and management of COPD in order to ensure effective 
strategies are implemented to stop people with early disease progressing.  
While previous studies involving patients with COPD in Australia have suggested 
suboptimal management,11,13 there is a lack of research involving practising Australian 
community-based general practitioners (GPs). The aim of this study was to gain insights 
into the initial diagnosis and early management practices for COPD amongst Australian 
primary care GPs, and to highlight any problem areas and management gaps, as 
determined by comparison with international-standard evidence-based management 
guidelines.  
Methods: 
A national postal questionnaire of Australian GPs was conducted. A total random 
sample of 1,000 GPs was approached; they were selected via the Medical Directory of 
Australia, an online medical database used to search and locate doctors and health 
facilities nationwide.14 The randomisation was undertaken independently by AMPCo 
Direct (Australasian Medical Publishing Company Ltd, Sydney). 
These selected GPs were sent an invitation letter and the survey. Replies were returned 
via an enclosed postage paid envelope. A follow-up reminder letter was sent to all the 
doctors three weeks after the initial letter was sent. The survey was 4 pages in length, 
and contained a total of 32 questions. All items were checkbox questions, except for the 
final item which allowed any additional comments relating to COPD diagnosis and 
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management. Completion of the survey was estimated to take approximately 10 minutes. 
The survey included questions about GP demographics and practice details, familiarity 
with contemporary practice guidelines, diagnosis of COPD, use of lung function tests, 
treatment preferences, advice offered and patient follow-up. A prize draw of an iPad 
mini was used as a recruitment incentive (to maintain anonymity, prize draw details 
were separated from survey responses immediately upon receipt).  
De-identified surveys were collected from June to October 2014. All variables were 
collated and entered into a statistical software package, SPSS version 21 (IBM, Armonk, 
New York, US). Respondents were classified as adherent or non-adherent to 
management guidelines according to their responses to four management areas: (i) using 
smoking history and spirometry to diagnose COPD, (ii) preferring bronchodilators (not 
inhaled corticosteroids) for initial treatment of COPD, (iii) routinely recommending 
pulmonary rehabilitation to patients with COPD and (iv) routinely offering smoking 
cessation advice to patients with smoking-related COPD.5,6 Those classified as adherent 
had to be following the recommendations in all four areas. 
Comparisons between adherent and non-adherent respondents were tested using the Chi 
Square test for dichotomous variables (with Yates’ Correction for Continuity) and the 
Mann-Whitney test for continuous variables, with P values of < 0.05 deemed 
statistically significant. A logistic regression analysis was performed to assess the 
validity of guideline adherence by looking at the impact of potentially related factors, 
with P < 0.1 used as a threshold for entry into the model. Variables that were used to 
classify respondents as adherent or non-adherent were excluded from the model. 
Variables that were closely related to adherence (e.g. views about spirometry and timing 
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of smoking cessation advice) were also excluded from the model. The study was 
approved by the Tasmanian Social Sciences Human Research Ethics Committee. 
Results: 
Of the 1,000 surveys distributed, 233 (23.3%) were completed and returned. The 
respondents were practicing in New South Wales (36.1%), Victoria (21.9%), 
Queensland (15.0%), Western Australia (10.3%), South Australia (8.2%), Tasmania 
(5.2%), Australian Capital Territory (0.4%) and the Northern Territory (0.9%). Most 
GPs practiced in an urban location (82.0%), and had a practice nurse present in the 
practice at which they worked (91.4%) (Table 1). 
The respondents used a variety of tools to diagnose COPD, with the majority basing a 
diagnosis on smoking history (94.4%), symptoms (91.0%), spirometry (88.8%) and 
physical examination (79.0%). Most respondents either had direct access to a spirometer 
(78.1%) or referred patients elsewhere for spirometry (20.2%), and 98.3% believed that 
spirometry testing is helpful in guiding a diagnosis. However, only 39.9% of 
respondents indicated that they record a formal diagnosis of COPD after the patient’s 
first presentation to them, with many GPs delaying the diagnosis until after a trial of 
pharmacotherapy (40.8%), after a respiratory specialist has made a diagnosis (20.2%) or 
after a diagnosis was made at hospital discharge (4.7%).  
While the majority (87.6%) of GPs indicated that they routinely communicate the 
diagnosis to patients, 31.8% used terms other than ‘chronic obstructive pulmonary 
disease’ or ‘COPD’ in this communication. The majority (88.8%) of respondents 
indicated that they routinely schedule follow-up visits with newly diagnosed patients 
(Table 2). 
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The majority (93.1%) of respondents believed that spirometry testing is helpful in 
guiding the management of COPD. Tiotropium was the preferred drug treatment in 
initial management by 77.3% of GPs, followed by short-acting beta-2 agonists (39.5%), 
inhaled corticosteroids (33.9%) and long-acting beta-2 agonists (29.6%). However, only 
27.5% indicated that they routinely recommend the non-pharmacological management 
option of pulmonary rehabilitation. Most GPs indicated that they routinely record 
patients’ smoking status (98.7%) and offer smoking cessation advice, but the timing of 
this advice varied, with 78.1% offering advice on a patient’s first presentation with 
respiratory symptoms, 11.2% waiting until a diagnosis of COPD has been made, 6.9% 
waiting until a follow-up visit and 3% waiting until the patient expresses an interest in 
quitting. (Table 3). 
Less than half (48.9%) of the respondents indicated that their management of COPD is 
informed by guidelines. The Australian COPD-X guidelines were the most popular 
resource used (30.0%), followed by the Therapeutic Guidelines (6.9%). Three-quarters 
(75.1%) of respondents indicated that they are aware of clinical tools and resources 
provided by the Australian Lung Foundation, but only 48.9% indicated that they 
routinely used these aids, and only 7.3% indicated that they were personally familiar 
with them (Table 4). Use of the chronic disease management GP services items 
available for reimbursement on the Medicare Benefits Schedule varied amongst 
respondents, with 41.2% indicating that they routinely use the General Practice 
Management Plan item and 36.5% routinely using the Team Care Arrangement Plan 
item.  
In total, 106 (45.5%) respondents could be classified as adherent to all four practice 
guideline areas of diagnosis, pharmacological management, pulmonary rehabilitation 
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and smoking cessation advice. Comparisons between GPs classed as adherent and non-
adherent to management guidelines are shown in Table 5. GPs who were adherent to 
management guidelines were more likely to report the presence of a regular nurse at 
their practice who routinely saw patients with COPD (P = 0.049), use the term ‘chronic 
obstructive pulmonary disease’ or ‘COPD’ when describing the diagnosis to patients 
(P = 0.081), use the General Practice Management Plan item (P = 0.002) and the Team 
Care Arrangement Plan item (P <0.001), and be familiar with (P = 0.004) and routinely 
use (P = 0.011) the Australian Lung Foundation’s tools and resources for GPs. The 
logistic regression model to predict the level of guideline adherence contained 7 
variables and was statistically significant overall (χ2 = 22.1, df = 7, P = 0.002); however, 
no independent variables made an independent uniquely significant contribution to the 
model.  
Discussion: 
Recent studies have demonstrated that the most rapid decline in lung function in COPD 
may occur in early to moderate disease,15,16 suggesting that diagnosing and treating 
patients early in their disease trajectory may offer the best chance at mitigating the 
substantial long-term morbidity and mortality associated with COPD. However, COPD 
is still underdiagnosed and undertreated in most countries, especially in its early 
stages.11,17-19 The present study indicates that COPD is often not diagnosed and 
managed in Australian primary care per the most recent recommendations and 
guidelines, and readily available resources are widely underutilised. Diagnosis of COPD 
is uniformly reactive, with no obvious attempt to case-find COPD among asymptomatic 
smokers. 
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While most GPs indicated that they base a diagnosis on smoking history, symptoms and 
spirometry, which is in accordance with guidelines, many GPs indicated that they often 
delay the diagnosis until after a trial of pharmacotherapy, after a respiratory specialist 
has made a diagnosis or after a hospital discharge diagnosis. This passive approach to 
diagnosis is consistent with other findings demonstrating that among patients meeting 
guideline criteria for COPD, many do not have a formal diagnosis from their GP, and 
are not receiving any treatment.11,19  
Interestingly, a previous qualitative study of GPs found that delayed diagnosis of COPD 
by GPs may be intentional, rationalised by a misperception of patients’ unwillingness to 
be given a diagnosis and GPs’ nihilistic attitudes to prognosis.20 However, it is now 
known that pharmacologic therapy initiated early in the course of COPD (in addition to 
smoking cessation) may alter the rate of disease progression.21-23 Establishing and acting 
on an early diagnosis of COPD is therefore a critical step in reducing the extensive 
morbidity and mortality of this disease. Achieving the goal of early diagnosis in COPD 
is clearly a significant challenge. While a number of studies have demonstrated the 
effectiveness of case-finding programs in general practice to diagnose COPD early,24-28 
a number of barriers reduce the implementation of such programs, including increased 
workload, and the need for assistance and financial compensation.29,30 
Prescribing preferences in the initial management of COPD were generally in 
accordance with guidelines, with most GPs indicating that they prescribed 
bronchodilators. However, ICS seemed to be over-prescribed, with one-third of GPs 
indicating that they were prescribed in addition to bronchodilators as initial therapy in 
early disease. While ICS have been shown to improve quality of life and lung function 
when added to bronchodilator therapy,31 they have been shown to increase the risk of 
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pneumonia in patients with COPD,32,33 and national management guidelines recommend 
that ICS be reserved for reduction in exacerbation rates in patients experiencing these 
frequently.5 Other studies around the world have also demonstrated ICS overuse in 
COPD, demonstrating suboptimal compliance with national and international 
guidelines.10,34-36 
Disappointingly, less than 30% of respondents indicated that they routinely recommend 
pulmonary rehabilitation to patients with COPD. While the reasons for this were not 
fully explored in this study, previous research suggests that low awareness of the health 
benefits of pulmonary rehabilitation and lack of availability of programs (or lack of 
knowledge about them) locally may be barriers to referral.12,37 Further strategies to 
enhance GPs’ access to, awareness and familiarity with pulmonary rehabilitation, to 
improve referral rates are warranted.  
GPs routinely recorded patients’ smoking status and offer smoking cessation advice, but 
the timing of this advice varied, with more than 20% of respondents indicating that they 
delayed smoking cessation advice, even once the patient had presented with respiratory 
symptoms, variably waiting until a diagnosis of COPD has been made, at some ill-
defined follow-up appointment, or only when the patient expresses an interest in 
quitting, whenever socially appropriate or after an infective exacerbation. This delay 
may be due to patient-based or GP-based barriers to providing opportunistic smoking 
cessation advice, such as the patient’s lack of motivation to quit, or time constraints, 
both of which have been described in previous research.38,39 While it is encouraging that 
almost 100% of respondents routinely offer smoking cessation advice to their patients, 
there is some room for improvement in when this advice is first offered, especially 
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considering that early smoking cessation in COPD has been shown to have a greater 
impact on lung function decline.40 
Less than half of the respondents indicated that their management of COPD is informed 
by guidelines. This is comparable to other studies outside of Australia.8,12 Increased 
awareness and implementation of guidelines and resources may improve screening of 
patients at risk and allow for earlier diagnosis of COPD. However, increased awareness 
and dissemination of guidelines alone may not necessarily translate into greater 
incorporation of such guidelines into practice. This was evidenced by three-quarters of 
respondents being aware of the Australian Lung Foundation’s tools and resources for 
GPs, but less than half indicating that they routinely use them in practice. The lack of 
personal familiarity with resources is of special concern. The Australian Lung 
Foundation has developed a range of clinical resources deigned to support general 
practice in the diagnosis and management of COPD; however, our results suggest a 
need for better ways of getting GPs familiar with and using their COPD management 
tools.  
There are some potential limitations to this study. The analysable response rate was only 
23% and so the data may not have provided a true representation of GPs’ practices. 
However, the response rate was typical of other surveys of doctors’ treatment 
practices,41-43 and was considered acceptable for this form of research, especially given 
the relatively long questionnaire (32 questions).44 Nevertheless, it should be borne in 
mind that the results may underestimate any evidence-to-practice gaps in Australia, as it 
is reasonable to assume that GPs may have been less likely to respond if they were 
uninterested in COPD, or unsure of or did not adhere to, current COPD management 
guidelines.  
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Notwithstanding these limitations, the results of this study provide valuable information 
regarding Australian prescribing and management practices in COPD. While previous 
studies involving patients with COPD in Australia have suggested suboptimal 
management,11,13 to our knowledge this is the first study to gain insight into these 
clinical issues from practising Australian GPs.  
Conclusion: 
There is considerable scope for major overall improvement in GPs’ use of and 
familiarity with COPD management guidelines, and the readily available tools and 
resources. The findings of this study highlight the need to devise strategies for 
improving clinical standards and so patient outcomes in COPD, and importantly by 
better use of resources already readily available. Compilation and dissemination of 
guidelines and focused education on some areas in need of improvement (such as 
delayed diagnosis, delayed smoking cessation advice and underutilisation of pulmonary 
rehabilitation) are important strategies for improving patient outcomes in COPD. 
Research in how to do all this more effectively should be a core part of any strategy, and 
should be recognised as a challenge for both the medical profession itself, and allied 
agencies such as the Australian Lung Foundation which produce the material that is so 
relatively under- or misused. 
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Table 1. Characteristics of responding general practitioners 
Survey item Responses† 
(n = 233) 
Gender  
Male 135 (57.9%) 
Female 98 (42.1%) 
Age 53 (26-87) 
Years registered 29 (2-64) 
Location of practice‡  
Urban 191 (82.0%) 
Rural 40 (17.2%) 
Hours per week seeing patients 38 (6-80) 
Patients seen per week (all) 120 (10-300) 
Patients seen per week (COPD) 7 (1-55) 
Presence of practice nurse(s) in practice 213 (91.4%) 
Number of full-time equivalent practice nurses 1 (0.3-6) 
Practice nurses who routinely see patients with COPD 112 (48.1%) 
Practice nurses specifically trained in COPD 47 (20.2%) 
†Values represent number (percent) of respondents or median (range).  
‡According to Section of State (Australian Bureau of Statistics).45 
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Table 2. Diagnosis of COPD 
Survey item Responses† 
(n = 233) 
Tools routinely used to diagnosis COPD  
Smoking history 220 (94.4%) 
Spirometry 207 (88.8%) 
Chest x-ray 154 (66.1%) 
COPD assessment test 23 (9.9%) 
Physical examination 184 (79.0%) 
Symptoms 212 (91.0%) 
Bronchodilator response 98 (42.1%) 
Spirometry – access   
Access to a spirometer 182 (78.1%) 
No access to a spirometer, but refer elsewhere 47 (20.2%) 
Spirometry – helpful in confirming diagnosis 229 (98.3%) 
Recording a formal diagnosis on first presentation‡ 93 (39.9%) 
Routinely communicate diagnosis to patient 204 (87.6%) 
Term(s) used to describe diagnosis to patient  
Chronic obstructive pulmonary disease / COPD 159 (68.2%) 
Other§ 74 (31.8%) 
Routinely schedules a follow-up visit with newly diagnosed 
COPD patient 
207 (88.8%) 
†Values represent number (percent) of respondents.  
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‡Other times when a formal diagnosis was recorded: after a trial of pharmacotherapy – 
95 (40.8%), after a respiratory specialist has diagnosed COPD – 47 (20.2%), after a 
hospital discharge – 11 (4.7%). 
§Other diagnostic terms: emphysema – 83 (35.6%), chronic bronchitis – 14 (6.0%), 
chronic obstructive airways disease – 4 (1.7%), asthma / adult-onset asthma/severe 
asthma – 3 (1.3%), lung damage – 2 (0.9%), smoker’s lungs / smoker’s damage – 2 
(0.9%), chronic airway limitation – 1 (0.4%). 
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Table 3. Pharmacological and non-pharmacological management of COPD 
Survey item Responses† 
(n = 233) 
Spirometry – helpful in guiding management 217 (93.1%) 
Preferred initial pharmacological management†  
Tiotropium 180 (77.3%) 
Long-acting beta-2 agonists 69 (29.6%) 
Ipratropium 31 (13.3%) 
Short-acting beta-2 agonists 92 (39.5%) 
Inhaled corticosteroids (ICS) 79 (33.9%) 
Other‡ 1 (0.4%) 
Routinely recommend pulmonary rehabilitation 64 (27.5%) 
Smoking status routinely recorded 230 (98.7%) 
Smoking cessation advice routinely offered 232 (99.6%) 
Timing of initial smoking cessation advice  
On first presentation with respiratory symptoms 182 (78.1%) 
Later§ 51 (21.9%) 
†Values represent number (percent) of respondents.  
‡Other pharmacological management preference: glycopyrronium. 
§Other times of smoking cessation advice: at time of diagnosis – 26 (11.2%), at time of 
follow-up – 16 (6.9%), whenever a patient expresses an interest in quitting – 7 (3.0%), 
whenever socially appropriate – 1 (0.4%), after an infective exacerbation – 1 (0.4%). 
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Table 4. Use of plans, guidelines, tools and resources 
Survey item Responses† 
(n = 233) 
Routinely use General Practice Management Plan (item 721) 96 (41.2%) 
Routinely use Team Care Arrangement Plan (item 723) 85 (36.5%) 
Use of management guidelines  
Management informed by guidelines 114 (48.9%) 
Australian Lung Foundation / COPD-X 70 (30.0%) 
Therapeutic Guidelines 16 (6.9%) 
Other‡ 19 (8.2%) 
Aware of Australian Lung Foundation’s tools and resources 175 (75.1%) 
Familiar with Australian Lung Foundation’s tools and resources  17 (7.3%) 
Routine use of Australian Lung Foundation’s tools and resources§ 114 (48.9%) 
†Values represent number (percent) of respondents.  
‡Other management guidelines used: international guidelines – 7 (3.0%), 
colleagues/specialists/professional meetings – 4 (1.7%), National Asthma Council – 3 
(1.3%), National Prescribing Service / continuing professional development activities – 
2 (0.9%), pharmaceutical representatives – 1 (0.4%), National Health and Medical 
Research Council – 1 (0.4%), Symbicort® Maintenance and Reliever Therapy – 1 
(0.4%). 
§Australian Lung Foundation’s tools and resources used: COPD Action Plan – 76 
(32.6%), Stepwise Management of Stable COPD – 38 (16.3%), Primary Care 
Respiratory Toolkit – 7 (3.0%), COPD Screening in General Practice – 36 (15.5%). 
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Table 5. Comparisons between GPs classed as adherent and non-adherent to 
COPD management guidelines 
Survey item Univariate analyses Logistic regression 
Adherent† 
(n = 106) 
Non-
adherent† 
(n = 127) 
P Odds 
ratio 
95% 
confidence 
interval 
P 
Presence of practice 
nurses who routinely 
see patients with 
COPD 
61 (57.5%) 51 (40.2%) 0.049 1.5 0.8-2.7 0.20
Use “chronic 
obstructive 
pulmonary disease” 
/ “COPD” to 
describe diagnosis to 
patients 
79 (74.5%) 80 (63.0%) 0.081 1.4 0.7-2.6 0.30
Routinely use 
General Practice 
Management Plan 
(item 721) 
56 (52.8%) 40 (31.5%) 0.002 0.9 0.3-2.9 0.86
Routinely use Team 
Care Arrangement 
Plan (item 723) 
52 (49.1%) 33 (26.0%) <0.001 2.0 0.6-6.8 0.26
Management of 62 (58.5%) 52 (40.9%) 0.013 1.5 0.8-2.7 0.20
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COPD informed by 
guidelines 
Familiar with 
Australian Lung 
Foundation’s tools 
and resources 
14 (13.2%) 3 (2.4%) 0.004 3.2 0.8-12.3 0.09
Routine use of 
Australian Lung 
Foundation’s tools 
and resources 
62 (58.5%) 52 (40.9%) 0.011 0.8 0.4-1.5 0.48
†Values represent number (percent) of respondents.  
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